US Drug Recall Register
Class II · Moderate risk Terminated Initiated Apr 13, 2022 (4 years ago)

Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations: Temperature abuse

What was recalled

Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment, 3.5 g tube, Rx only MFG: Sandoz, NDC 61314-631-36

Recalling firm
Mckesson Medical-Surgical Inc. Corporate Office
NDC code
61314-631-36
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1102-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Dexamethasone recalls

See all
Class II · Moderate risk Ongoing

Dexamethasone Sodium Phosphate Injection

Reason Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.

Somerset Therapeutics LLC D-0398-2026
Class II · Moderate risk Ongoing

Dexamethasone Moxifloxacin Ketorolac

Reason Presence of particulate matter - Glass like particles.

Imprimis NJOF, LLC NDC 71384-513-01 D-0250-2026
Class II · Moderate risk Ongoing

Dexamethasone Moxifloxacin

Reason Presence of particulate matter - Glass like particles.

Imprimis NJOF, LLC NDC 71384-512-0 D-0249-2026
Class II · Moderate risk Ongoing

Dexonto 0.4%

Reason Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.

Nubratori, Inc NDC 71300-6564-1 D-0392-2025